Northwest Biotherapeutics Q4 2024 Earnings Report

Northwest Biotherapeutics EPS Results

• Actual EPS: -$0.02
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Northwest Biotherapeutics Revenue Results

• Actual Revenue: $0.23 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Northwest Biotherapeutics Announcement Details

• Quarter: Q4 2024
• Date: 3/31/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Northwest Biotherapeutics (OTCMKTS:NWBO) is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial. In addition, Northwest Biotherapeutics is evaluating DCVax®-Direct, a novel formulation intended for direct injection into solid tumors, in Phase I/II studies. The company maintains an active pipeline exploring applications of its dendritic cell platform in other oncology indications.

Headquartered in Bethesda, Maryland, Northwest Biotherapeutics collaborates with research institutions and clinical centers across North America and Europe. These partnerships support ongoing trials, manufacturing scale-up, and regulatory interactions. The company’s leadership team comprises industry veterans with expertise in immunology, clinical development, and regulatory affairs, all working to advance personalized immunotherapy as a new standard of care in oncology.